Compare Freeport-McMoRan Inc (FCX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Incyte Corporation — how do they compare? Freeport-McMoRan Inc trades at $69.45 (market cap $96.42B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Freeport-McMoRan Inc is far larger — about 3.9× Incyte Corporation's market cap, and Freeport-McMoRan Inc pays a 0.87% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FCX | INCY | |
|---|---|---|
Market Cap | $96.42B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $129.93 |
52-Week Low | $35.34 | $81.61 |
Enterprise Value | $102.70B | $20.04B |
Dividend Yield | 0.87% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
